Importantly, the reduction in sRAGE serum levels correlated with the severity of neurological deficits (Supplemental Figure 7B), suggesting enhanced RAGE activation in NMO and highlighting the potential of sRAGE as a marker for the autoimmune-mediated inflammatory activity and clinical outcomes in NMO. The gene discussed is AGER; the disease is neuromyelitis optica.